Qiagen Expects $557M from Public Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen expects to raise gross proceeds of around $557 million from a public offering of newly issued common shares.

The firm said last night that it will offer 27.5 million shares at a price of $20.25 per share. Qiagen's shares closed at $21.02 in Thursday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.